卫信康(603676) - 卫信康投资者关系活动记录表

Financial Performance - Revenue for the first half of 2024 was 633 million yuan, a decrease of 15.50% year-on-year [2] - Net profit attributable to shareholders was 163 million yuan, an increase of 21.98% year-on-year [2] - Total assets as of June 30, 2024, were 1.929 billion yuan, with current assets of 1.363 billion yuan [2] - Net cash flow from operating activities was 191 million yuan, indicating strong liquidity [2] R&D and Product Development - The company has over 40 new product projects in development, focusing on perioperative medication, medical aesthetics, and patches [2][3] - Efforts are being made to accelerate product acquisition through BD and joint development to enhance the product portfolio [3] - The company is actively responding to national medical reform policies, focusing on high-quality development of generic drugs [2] Market Strategy and Future Outlook - The company is leveraging opportunities from core products entering centralized procurement directories [3] - New products like multi-trace element injection (III) and multi-trace element injection (I) are expected to drive future sales [3] - The company plans to expand market coverage and enter new development phases by following industry trends [3] Corporate Governance and Investor Relations - The company held a performance briefing on September 4, 2024, at the Shanghai Stock Exchange Roadshow Center [1][4] - Key executives, including the Chairman, General Manager, and CFO, participated in the Q&A session to address investor concerns [1][2] - The company expressed gratitude to investors for their support and emphasized the importance of their feedback for future improvements [3]